Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma : a subgroup analysis of a phase 2 study
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma : a subgroup analysis of a phase 2 study
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma : a subgroup analysis of a phase 2 study
author:
Salles Gilles, Schuster Stephen J., de Vos Sven, Wagner-Johnston Nina D., Viardot Andreas, Blum Kristie A., Flowers Christopher R., Jurczak Wojciech , Flinn Ian W., Kahl Brad S., Martin Peter, Kim Yeonhee, Shreay Sanatan, Will Matthias, Sorensen Bess, Breuleux Madlaina, Zinzani Pier Luigi, Gopal Ajay K.